ARS Pharmaceuticals financials
$4.40+6.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.7M | $22.7M | $28.1M | $32.5M | $15.7M | $8.0M | $86.6M | $2.1M | $500.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $20.8M | $16.4M | $21.9M | $24.3M | $10.7M | $6.9M | $85.7M | $2.0M | $500.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | 61.8% | 72.3% | 78.1% | 74.8% | 68.3% | 86.3% | 99.0% | 94.6% | 100.0% | — | — | — |
| Operating income | -$61.5M | -$60.1M | -$41.5M | -$53.2M | -$47.6M | -$37.2M | $47.2M | -$21.7M | -$15.3M | -$13.2M | -$10.2M | -$18.0M |
| Net income | -$62.3M | -$60.6M | -$41.1M | -$51.1M | -$44.9M | -$33.9M | $49.6M | -$18.6M | -$12.5M | -$10.3M | -$7.2M | -$14.9M |
| Net margin | −185.2% | −267.3% | −146.3% | −157.3% | −285.6% | −425.7% | 57.3% | −901.5% | −2503.2% | — | — | — |
| Diluted EPS | $-0.63 | $-0.61 | $-0.41 | $-0.52 | $-0.46 | $-0.35 | $0.42 | $-0.20 | $-0.13 | $-0.11 | $-0.07 | $-0.16 |
| EBITDA | -$61.0M | -$59.7M | -$41.0M | -$52.8M | -$47.3M | -$36.9M | $47.2M | -$21.7M | -$15.3M | -$13.2M | -$5.1M | -$23.1M |
| Operating cash flow | -$60.9M | -$44.9M | -$43.5M | -$47.0M | -$39.6M | -$40.7M | $42.0M | -$14.5M | -$7.3M | -$6.7M | -$17.4M | -$12.8M |
| Free cash flow | -$60.9M | -$44.9M | -$43.5M | -$47.2M | -$39.6M | -$40.8M | $41.7M | -$14.6M | -$7.3M | -$6.8M | -$17.5M | -$12.8M |
| Diluted shares | 99.3M | 99.3M | 99.0M | 98.8M | 98.4M | 98.1M | 119.2M | 97.0M | 96.8M | 96.5M | 96.1M | 95.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.2M | $24.3M | $41.3M | $59.6M | $51.5M | $39.9M |
| Short-term investments | $135.7M | $176.6M | $203.7M | $228.7M | $188.6M | $235.9M |
| Total debt | $171.6M | $171.2M | $168.5M | $168.3M | $72.0M | $69.4M |
| Total assets | $249.5M | $287.6M | $327.7M | $372.8M | $313.5M | $327.3M |
| Total liabilities | $237.0M | $226.3M | $213.4M | $225.1M | $121.2M | $98.3M |
| Shareholders' equity | $12.5M | $61.3M | $114.3M | $147.7M | $192.3M | $229.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology